DEFM14A: Alcon to Acquire LENSAR for $14.00 Per Share Plus Contingent Value Right

Alcon Research, LLC is set to acquire LENSAR, Inc. for $14.00 per share in cash plus a contingent value right (CVR) of up to $2.75 per share, pending stockholder approval.

Summary

• LENSAR, Inc. has entered into a merger agreement with Alcon Research, LLC, a subsidiary of Alcon Inc., where Alcon will acquire LENSAR.
• Under the agreement, Alcon will pay $14.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR represents the right to receive an additional $2.75 in cash if a milestone is achieved.
• The milestone requires 614,000 cumulative Milestone Procedures between January 1, 2026, and December 31, 2027.
• The merger consideration represents a premium of approximately 24% to LENSAR's volume weighted average closing sale prices on Nasdaq during the 30-day trading period ended March 21, 2025, assuming the achievement of the milestone set forth in the CVR Agreement.
• The merger consideration represents a premium of approximately 47% to LENSAR's volume weighted average closing sale prices on Nasdaq during the 90-day trading period ended March 21, 2025, assuming the achievement of the milestone set forth in the CVR Agreement.
• If the milestone is not achieved, the merger consideration represents a premium of approximately 4% to LENSAR's volume weighted average closing sale prices on Nasdaq during the 30-day trading period ended March 21, 2025.
• If the milestone is not achieved, the merger consideration represents a premium of approximately 23% to LENSAR's volume weighted average closing sale prices on Nasdaq during the 90-day trading period ended March 21, 2025.
• North Run Capital Partners, LP and NR-GRI Partners, LP, holding approximately 45.8% of the outstanding voting power, have agreed to vote in favor of the merger.
• The transaction is subject to customary closing conditions, including stockholder approval and regulatory approvals.
• The Board of Directors of LENSAR unanimously recommends that stockholders vote in favor of the merger.
• The special meeting to vote on the merger will be held virtually on July 2, 2025.
• Wells Fargo Securities, LLC rendered an opinion to the Board of Directors of LENSAR that the Merger Consideration to be received by such holders in the Merger pursuant to the Merger Agreement was fair, from a financial point of view, to the holders of shares of LENSAR Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. The deal offers a premium to shareholders, but the contingent value right introduces uncertainty. The backing of major shareholders and the board's recommendation are positive signals.

Positives

• Stockholders will receive $14.00 per share in cash at closing.
• There is potential for an additional $2.75 per share via the CVR.
• The deal provides a significant premium over recent trading prices.
• Major shareholders support the transaction.
• The merger provides liquidity and certainty of value to LENSAR stockholders.

Negatives

• The additional $2.75 per share is contingent and may not be realized.
• The CVR is non-transferable and will not be listed on any securities exchange.
• The CVR's value is dependent on Alcon's performance and strategic decisions post-acquisition.
• The transaction will result in LENSAR ceasing to be a publicly traded company.

Risks

• The milestone for the CVR may not be achieved.
• Regulatory approvals may delay or prevent the transaction.
• The deal could be terminated under certain circumstances, requiring LENSAR to pay a termination fee.
• The loss of key personnel during the pendency of the merger could impact LENSAR's business.
• The law is unclear as to the U.S. federal income tax treatment of the CVRs, the amount of gain or loss a holder recognizes, and the timing and character of such gain or loss, is uncertain.

Future Outlook

The merger is expected to be consummated in mid-to-late 2025, subject to the satisfaction or waiver of all closing conditions.

Management Comments

• The Board of Directors of LENSAR unanimously recommends that stockholders vote in favor of the merger.

Industry Context

The acquisition of LENSAR by Alcon, a global leader in eye care, reflects a trend of consolidation in the medical device industry. Alcon's acquisition of LENSAR will allow Alcon to expand its product portfolio and market share in the cataract surgery market.

Comparison to Industry Standards

• Comparable acquisitions in the medical device space often involve a premium over the target's current market price.
• The premium offered in this deal is within the range of premiums observed in similar transactions.
• The use of a CVR is a common mechanism to bridge valuation gaps and share future upside potential.
• Other companies in the ophthalmic surgical device market, such as Johnson & Johnson Vision, Carl Zeiss Meditec, and Topcon, are also active acquirers of innovative technologies.

Stakeholder Impact

• Shareholders will receive cash and a potential CVR payment.
• Employees face potential changes in compensation and benefits post-merger.
• Customers may see changes in product offerings and service.
• Suppliers may be affected by Alcon's supply chain management.

Next Steps

• LENSAR will hold a special meeting of stockholders on July 2, 2025, to vote on the merger agreement.
• The parties will seek regulatory approvals.
• If approved, the merger is expected to close in mid-to-late 2025.

Key Dates

Keywords

merger, acquisition, LENSAR, Alcon, CVR, stockholders, agreement, consideration, milestone, voting